Singular Genomics Systems (OMIC) Stock Price, News & Analysis

Company Overview

Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue. Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California.

Key Stats

• Today's Range: $19.96 to $20.01
• 50-Day Range: $19.26 to $20.07
• 52-Week Range: $5.34 to $23.41
• Volume: 7,900 shs
• Average Volume: 9,919 shs
• Market Capitalization: $50.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.75
• Consensus Rating: Hold

Singular Genomics Systems Stock Analysis - MarketRank™

Singular Genomics Systems scored higher than 32% of companies evaluated by MarketBeat, and ranked 792nd out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Singular Genomics Systems has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Singular Genomics Systems has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Singular Genomics Systems is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Singular Genomics Systems is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Singular Genomics Systems has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.91% of the float of Singular Genomics Systems has been sold short.

Short Interest Ratio / Days to Cover

Singular Genomics Systems has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Singular Genomics Systems has recently decreased by 1.32%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Singular Genomics Systems does not currently pay a dividend.

Dividend Growth

Singular Genomics Systems does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.91% of the float of Singular Genomics Systems has been sold short.

Short Interest Ratio / Days to Cover

Singular Genomics Systems has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Singular Genomics Systems has recently decreased by 1.32%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.71

News Sentiment

Singular Genomics Systems has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Singular Genomics Systems this week, compared to 1 article on an average week.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Singular Genomics Systems insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,541.00 in company stock.

Percentage Held by Insiders

22.20% of the stock of Singular Genomics Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

65.80% of the stock of Singular Genomics Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OMIC Stock Analysis - Frequently Asked Questions

How have OMIC shares performed this year?

Singular Genomics Systems' stock was trading at $19.43 on January 1st, 2025. Since then, OMIC stock has increased by 3.0% and is now trading at $20.0090.
View the best growth stocks for 2025 here.

How were Singular Genomics Systems' earnings last quarter?

Singular Genomics Systems, Inc. (NASDAQ:OMIC) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($6.72) EPS for the quarter, topping analysts' consensus estimates of ($8.05) by $1.33. The firm earned $0.41 million during the quarter, compared to analysts' expectations of $0.74 million. Singular Genomics Systems had a negative trailing twelve-month return on equity of 57.87% and a negative net margin of 3,237.89%.

When did Singular Genomics Systems' stock split?

Shares of Singular Genomics Systems reverse split on the morning of Wednesday, June 26th 2024. The 1-30 reverse split was announced on Wednesday, June 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Singular Genomics Systems IPO?

Singular Genomics Systems (OMIC) raised $178 million in an IPO on Thursday, May 27th 2021. The company issued 8,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Goldman Sachs, BofA Securities, Cowen and UBS Investment Bank served as the underwriters for the IPO.

Who are Singular Genomics Systems' major shareholders?

Top institutional investors of Singular Genomics Systems include JPMorgan Chase & Co. (0.08%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Eli N Glezer, Michael J Pellini and Andrew Spaventa.
View institutional ownership trends.

How do I buy shares of Singular Genomics Systems?

Shares of OMIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Singular Genomics Systems own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Singular Genomics Systems investors own include NVIDIA (NVDA), Tesla (TSLA), Albemarle (ALB), CrowdStrike (CRWD), Etsy (ETSY), Ford Motor (F) and Fluence Energy (FLNC).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 2/21/2025
• Next Earnings (Estimated): 3/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:OMIC
• CUSIP: N/A
• CIK: 1850906
• Web: singulargenomics.com
• Phone: 858-333-7830
• Fax: N/A
• Employees: 220
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.75
• High Stock Price Target: $15.00
• Low Stock Price Target: $6.50
• Potential Upside/Downside: -46.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($35.1096)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-94,820,000.00
• Net Margins: -3,237.89%
• Pretax Margin: -3,237.89%
• Return on Equity: -57.87%
• Return on Assets: -37.90%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 7.37
• Quick Ratio: 6.67

Sales & Book Value

• Annual Sales: $2.91 million
• Price / Sales: 17.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $73.25 per share
• Price / Book: 0.27

Miscellaneous

• Outstanding Shares: 2,540,000
• Free Float: 1,974,000
• Market Cap: $50.82 million
• Optionable: Optionable
• Beta: 1.83